Key Facts
Consortium & Activities
ACTTIVAC brings together seven organisations from four countries, combining expertise in vaccine development, clinical trials, immunology, data management, technology transfer, and manufacturing. The consortium has been designed to support high-quality research, regional relevance, and the long-term impact for TB vaccine innovation in Africa.
Objectives
Consortium Partners
Tuberculosis Vaccine Initiative (TBVI)
Netherlands
TBVI contributes expertise in TB vaccine development strategy, project coordination, and management of EU- and EDCTP-funded projects. The organisation has also helped establish the TB Vaccine Development Pathway used in the field.
Access to Advanced Health
United Kingdom
Access to Advanced Health has extensive experience in adjuvant formulation and translational vaccine development. The organisation leads technology transfer activities related to vaccine development and supply for the project.
Southern African TB Vaccine Initiative (SATVI)
South Africa
SATVI contributes major expertise in TB vaccine clinical research, trial implementation, and immunology. SATVI has conducted numerous phase 1-4 clinical trials and has strong laboratory capability to support TB vaccine studies.
The Aurum Institute
South Africa
The Aurum Institute contributes extensive clinical trial experience and will support trial implementation and workforce development through the structured internship programme. The organisation has a strong track record in TB vaccine research across multiple sites.
BioInformatiCo
South Africa
BioInformatiCo contributes expertise in clinical data management, project support, and regional research operations. The organisation will support the collection, collation, and management of participant and trial-related data.
Obafemi Awolowo University
Nigeria
OAU leads the field-based thermostability component in Nigeria and contributes expertise in physicochemical stability and analytical methods. The institution plays an important role in evaluating vaccine performance under real-world storage conditions.
Key Facts
Study Activities
The ACTTIVAC project combines clinical research, capacity strengthening, manufacturing readiness, and field-based stability testing. Together, these activities are designed to support the next stages of development for the ID93+GLA-SE vaccine candidate.
Clinical Trial
Phase 2a clinical trial
The phase 2a trial will evaluate the safety and immunogenicity of the lyophilised single-vial ID93+GLA-SE vaccine at four dose levels compared with placebo in approximately 240 previously BCG-vaccinated, MTB-sensitised, and MTB-unsensitised adolescents and adults aged 15-44 years. The trial will be conducted at two sites in South Africa: Worcester through SATVI and Klerksdorp through The Aurum Institute.
Workforce
Capacity strengthening
A structured 2-year internship programme will support the recruitment and training of aspiring clinical research professionals from local communities. The programme will include certification, role-specific training, hands-on experience, and mentorship in areas such as regulatory affairs, laboratory operations, data management, quality systems, and participant recruitment.
2 Yrs
Programme length
5 Areas
Programme length
Workforce
Technology Transfer
ACTTIVAC includes the transfer of GLA-SE adjuvant production technology from Access to Advanced Health. This work is intended to support future GMP manufacturing capacity in South Africa and contribute to longer-term local production.
Workforce
Field testing of thermostability
The project also includes a field-based stability study in Nigeria led by Obafemi Awolowo University. Vaccine vials will be monitored in healthcare facilities under real-world room-temperature conditions to assess whether the product maintains acceptable stability over time.
Full disclaimer:
Funded by the European Union under Global Health EDCTP3. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of Global Health EDCTP3 nor its members. Neither of the parties can be held responsible for them..